PMID: 39307Jun 21, 1979

A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia

Lars Gunne, S Bárány


Two Cebus apella monkeys with haloperidol-induced tardive dyskinesia have been studied. Substitution of chlorpromazine, thioridazine, clozapine, melperone, or fluphenazine for the daily haloperidol administration temporarily reduced the signs of tardive dyskinesia. In a monkey with low-grade symptoms, persisting for more than 100 days after withdrawal of haloperidol, neuroleptic drugs induced a typical sequence of events: first the dyskinetic movements were abolished, but 1--3 days after administration of a single dose of a neuroleptic drug there was a rebound worsening of symptoms. It was noticed that this aggravation of symptoms corresponded in magnitude and duration to the approximate liability of each compound to induce tardive dyskinesia in man. It is therefore suggested that this animal model could be used to monitor neurological side effects in neuroleptic drugs.


Jan 1, 1983·Psychopharmacology·N BjørndalE Christensson
Jan 1, 1983·Psychopharmacology·B WistedtA Jørgensen
Jan 1, 1984·Psychopharmacology·S KorsgaardJ Gerlach
Jan 1, 1981·Psychopharmacology·Roger D Porsolt, M Jalfre
Dec 1, 1986·Pharmacology, Biochemistry, and Behavior·L A RodriguezM L Camarena
Oct 1, 1986·Pharmacology, Biochemistry, and Behavior·Lars GunneP Johansson
Aug 1, 1983·Brain Research Bulletin·R L Borison, B I Diamond
Dec 1, 1991·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H LublinE Tolvanen
Jul 26, 1980·Lancet·U KniggeP M Christiansen
Jul 26, 1980·Lancet·W T CarpenterJ H Stephens
Jan 30, 2002·Psychiatry Research·H Y MeltzerKaru Jayathilake
May 27, 2003·Schizophrenia Research·Tomiki SumiyoshiHerbert Y Meltzer
Mar 13, 2012·Behavioral and Brain Functions : BBF·Pierre J BlanchetDaniel Lévesque
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Rebecka KlintenbergPer E Andrén
Apr 5, 2013·The European Journal of Neuroscience·Souha MahmoudiDaniel Lévesque
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·L Bjerkenstedt
Jan 1, 1984·Acta Psychiatrica Scandinavica. Supplementum·J Gerlach, D E Casey
Jan 1, 1984·Acta Psychiatrica Scandinavica. Supplementum·J E Häggström
Dec 1, 1988·The Australian and New Zealand Journal of Psychiatry·P Sachdev
Jan 1, 1981·Acta Psychiatrica Scandinavica. Supplementum·J Gerlach
Jan 1, 1981·Acta Psychiatrica Scandinavica. Supplementum·K E Moore
Sep 14, 2013·The Journal of Pharmacology and Experimental Therapeutics·Roger D PorsoltDavid Virley
Feb 1, 1983·Acta Pharmacologica Et Toxicologica·D F Smith, A Amdisen
Apr 1, 1988·Acta Psychiatrica Scandinavica·J Gerlach, D E Casey


Jan 1, 1977·Progress in Neuro-psychopharmacology·G GardosR A La Brie
Sep 27, 1975·Lancet·J Idänpään-HeikkiläI Palva
Nov 24, 1976·Psychopharmacology·Lars Gunne, S Bárány
Mar 11, 1977·European Journal of Clinical Pharmacology·J Idänpään-HeikkiläI P Palva
Apr 1, 1973·The British Journal of Psychiatry : the Journal of Mental Science·G E Crane

Related Concepts

Antipsychotic Effect
Behavior, Animal
Assay OF Haloperidol
Lingual-Facial-Buccal Dyskinesia
Tardive Dyskinesia

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here